These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7886413)

  • 1. Oestrogen receptor investigations in bladder tumours.
    Kvist E; Albrectsen J
    Scand J Urol Nephrol; 1994 Dec; 28(4):369-70. PubMed ID: 7886413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Undifferentiated small-cell carcinoma of the urinary bladder].
    Suárez Vilela D; Salas Valien JS; González Morán MA; Giménez Pizarro A
    Arch Esp Urol; 1991 Dec; 44(10):1195-8. PubMed ID: 1667892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
    Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
    J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.
    Guo CC; Fine SW; Epstein JI
    Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of estrogen receptors and progesterone receptors in transitional cell carcinoma of bladder.
    Shan Y; Li L; Yan C; Yin F
    Chin Med J (Engl); 1998 Feb; 111(2):191-2. PubMed ID: 10374388
    [No Abstract]   [Full Text] [Related]  

  • 6. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.
    Byrne RR; Shariat SF; Brown R; Kattan MW; Morton RA JR; Wheeler TM; Lerner SP
    J Urol; 2001 May; 165(5):1473-9. PubMed ID: 11342899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mapping of histology and cell proliferation in human bladder cancer: an immunohistochemical study.
    Igawa M; Urakami S; Shirakawa H; Shiina H; Ishibe T; Usui T; Moriyama H
    Hiroshima J Med Sci; 1995 Dec; 44(4):93-7. PubMed ID: 8857231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of tissue ABH antigens in superficial bladder tumours.
    Tsujihashi H; Matsuda H; Uejima S; Akiyama T; Kurita T
    Int Urol Nephrol; 1991; 23(1):37-44. PubMed ID: 1938218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights from a whole cystectomy specimen--association of primary small cell carcinoma of the bladder with transitional cell carcinoma in situ.
    Gaisa NT; Tilki D; Losen I; Dahl E; Stoehr R; Stief CG; Knüchel R
    Hum Pathol; 2008 Aug; 39(8):1258-62. PubMed ID: 18547617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavior of epithelial differentiation antigens (carcinoembryonic antigen, epithelial membrane antigen, keratin and cytokeratin) in transitional cell carcinomas of the bladder.
    Sánchez-Fernández de Sevilla MC; Morell-Quadreny L; Gil-Salom M; Pérez-Bacete M; Fenollosa-Entrena B; Llombart-Bosch A
    Urol Int; 1992; 48(1):14-9. PubMed ID: 1376008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood group antigens and bladder carcinoma: a perspective.
    Stein BS; Kendall AR
    Urology; 1982 Sep; 20(3):229-33. PubMed ID: 7123712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
    McKenney JK; Desai S; Cohen C; Amin MB
    Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of blood groups and transitional cell carcinoma of the bladder.
    Kirkali Z; Eryigit M
    Int Urol Nephrol; 1993; 25(3):255-7. PubMed ID: 8225826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinoma in situ as a prognostic factor for G3pT1 bladder tumours.
    Vicente J; Laguna MP; Duarte D; Algaba F; Chéchile G
    Br J Urol; 1991 Oct; 68(4):380-2. PubMed ID: 1933158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of A,B and H blood group antigens in urothelial carcinoma of the urinary bladder].
    Tichý M; Tichá V; Jansa P; Student V; Vanák J
    Cesk Patol; 1991 Mar; 27(1-2):13-9. PubMed ID: 1893425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
    Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
    J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologist's role in bladder cancer.
    Farrow GM
    Semin Oncol; 1979 Jun; 6(2):198-206. PubMed ID: 482961
    [No Abstract]   [Full Text] [Related]  

  • 18. Transitional cell carcinoma of the bladder mimicking lobular carcinoma of the breast: a discohesive variant of urothelial carcinoma.
    Baldwin L; Lee AH; Al-Talib RK; Theaker JM
    Histopathology; 2005 Jan; 46(1):50-6. PubMed ID: 15656886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
    Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
    Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of urine cytology with ABO(H) antigenicity in transitional cell carcinoma of the bladder.
    Das G; Glashan RW
    J Clin Pathol; 1988 May; 41(5):538-9. PubMed ID: 3384984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.